The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in …

Rare CNS TumorFOXR2-activatedBCOR ITD Sarcoma+3 more

~Estimated

~$10 – $7,500

Adriana FonsecaNCT07851636

Phase 1

Phase I Clinical Trial of GPC2 Chimeric Antigen Receptor T (GPC2-CAR T) Cells for Relapsed or Refractory Medulloblastoma in Children and Young Adults

This is a single-site, open-label Phase I treatment study evaluating the manufacturing feasibility and safety of chimeric antigen receptor (CAR) T cells target…

MedulloblastomaCentral Nervous System Embryonal TumorRefractory Medulloblastoma+7 more

~Estimated

~$10 – $6,250

Stanford UniversityNCT07087002